4//SEC Filing
Haas Jason 4
Accession 0001209191-23-054172
CIK 0001556263other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 4:53 PM ET
Size
9.1 KB
Accession
0001209191-23-054172
Insider Transaction Report
Form 4
Haas Jason
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-10-31+18,875→ 20,252 total - Tax Payment
Common Stock
2023-11-01$2.22/sh−6,301$13,988→ 13,951 total - Exercise/Conversion
Restricted Stock Units
2023-10-31−18,875→ 18,875 total→ Common Stock (18,875 underlying)
Footnotes (4)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024.
Documents
Issuer
Syros Pharmaceuticals, Inc.
CIK 0001556263
Entity typeother
Related Parties
1- filerCIK 0001883821
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 4:53 PM ET
- Size
- 9.1 KB